Stroke | Boehringer Ingelheim MEA
Stroke
Acute ischaemic stroke, the most common type of stroke, occurs when the blood supply to part of the brain is blocked by either a blood clot in a brain vessel or atherosclerosis (fatty deposits or plaques lining vessel walls). A stroke can lead to disability or even death and always requires quick, acute treatment. Boehringer Ingelheim led the way in stroke care by developing the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, which is now used in stroke centres worldwide. Boehringer Ingelheim also sponsors the angels initiative: a programme that helps doctors to set up and optimise acute stroke networks with the support of local and international stroke societies.
Stroke, don’t stay at home!
Learn why the Angels Initiative is urging anyone who experiences stroke symptoms to seek immediate medical care, even during the pandemic
Read more
Telling my story...AF and DVT/PE Patient Voices
Telling my story...AF and DVT/PE Patient Voices
Telling My Story is a video series featuring stories from across the world from patients with atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE).
The Angels Initiative
The Angels Initiative is a unique healthcare initiative to improve acute care for people who have just suffered a stroke
Angels Initiative in South Africa
Angels Initiative in South Africa
Listen to Dr Anastasia Rossouw and find out how the Angels Initiative is making a difference for stroke patients in South Africa
Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE
February 22, 2025
Read more
World Stroke Organization Honors Eight Stroke Centers powered by Angels Award for their Efforts in developing stroke management in Egypt
April 06, 2021